FDA approves J&J Vision’s therapeutic contact lenses for myopia
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

FDA approves J&J Vision’s therapeutic contact lenses for myopia

13 May 2021 (Last Updated May 13th, 2021 12:31)

Johnson & Johnson Vision’s overnight therapeutic lenses receive FDA approval for myopia.

FDA approves J&J Vision’s therapeutic contact lenses for myopia
According to clinical studies, ortho-k lenses were found to be a safe and efficient option for myopia management. Credit: slavoljubovski from Pixabay.

The US Food and Drug Administration (FDA) has approved Johnson & Johnson Vision’s (J&J) ACUVUE Abiliti Overnight Therapeutic Lenses for managing myopia.

J&J noted that these lenses are the first orthokeratology (ortho-k) contact lens to receive FDA approval in this indication. According to clinical studies, ortho-k lenses were a safe and efficient option for myopia management.

Tailored to match a patient’s eye depending on its corneal shape, Abiliti Overnight ortho-k contact lenses can reshape the cornea temporarily.

To be available by the end of the year in the US, the contact lens will come in two designs, Abiliti Overnight Therapeutic Lenses and Abiliti Overnight Therapeutic Lenses for Astigmatism.

J&J research and development global head Xiao-Yu Song said: “The FDA approval of Abiliti Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia.

“We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses and continuing with additional products and services to address the progression of myopia.”

Abiliti Overnight contact lenses feature corneal topography, refractive error and other measurements linked to a fitting software.

This user-friendly software offers an exact measure of the corneal shape and precisely guides the eye care specialist during the fitting procedure for first fit rates of about 90%.

J&J paid consultant Dr Moshe Mendelson said: “The prevalence of myopia in children is increasing, and as optometrists, we are on the front lines of this epidemic that may threaten the vision of future generations.

“For too long we have relied on increasing the prescription of glasses for children while having few resources to address the underlying disease and help change this worrying trajectory of eye health.”

The company noted that the latest FDA approval for the lens is a result of its partnership with Menicon to develop therapeutic contact lenses for myopia under the ACUVUE Abiliti brand.